Engineered immune cells take aim at tough T-Cell cancers

NCT ID NCT06316856

Recruiting now Disease control Sponsor: Beijing GoBroad Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times

Summary

This study tests a new treatment called CD5 CAR T cells for people with T-cell blood cancers that have come back or not responded to standard therapy. About 54 participants will receive specially engineered immune cells designed to find and attack cancer cells. The goal is to check safety and see if the treatment can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing GoBroad Hospital
RECRUITING

Beijing, Beijing Municipality, 102206, China
Shanghai Liquan Hospital
RECRUITING

Shanghai, Shanghai Municipality, 201418, China
The General Hospital of Western Theater Command PLA
NOT_YET_RECRUITING

Chengdu, Sichuan, 610083, China
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
RECRUITING

Shanghai, Shanghai Municipality, 200435, China

Conditions

Explore the condition pages connected to this study.

ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA T-CELL ACUTE LYMPHOCYTIC LEUKEMIA T-CELL ACUTE LYMPHOCYTIC LEUKEMIA T-CELL MALIGNANCIES T-CELL MALIGNANCIES